On April 23, 2021, a phase IIa clinical trial kick-off meeting of class 1 innovative drug antinotriol injection of Guangzhou saipute Medical Technology Co., Ltd. was successfully held in the Department of Neurology of the army characteristic medical center of the Chinese people's Liberation Army (Chongqing Daping Hospital). The trial will be undertaken by Professor Zhang Meng of NCU of Daping Hospital. It is a randomized, double-blind and placebo-controlled clinical study aimed at exploring the safety and effectiveness of antinotriol injection combined with intravascular thrombectomy in the treatment of acute ischemic stroke (registration number of drug clinical trial registration and information publicity platform: ctr20192118). This study will provide key clinical evidence for further confirming the safety of antinotriol in human body, especially in patients with central nervous system diseases, and verifying its neuroprotective mechanism and efficacy. The trial is expected to take 18 months and the research data will be published in mid-2022.